ClinicalTrials.gg
CompletedNCT01632904Updated Nov 14, 2017Results posted

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

A Phase 3 interventional study of Ruxolitinib and Hydroxyurea (HU) in Polycythemia Vera, sponsored by Incyte Corporation. Completed at 70 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.

Enrollment
9th of 17
110 · median 110
Started
2012
the only one that year
Phase 3
5 of 17
1 open now
Registered
5th of 17
by date
Lead sponsor
3 of 17
Incyte Corporation

Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 5 in phase 3, and was the 5th registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing ruxolitinib in Polycythemia Vera, or all of them as a file.
02

Study summary

The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.

Read the detailed description

This is a Phase 3 multicenter, double-blind, double-dummy, randomized study. Only subjects with PV who have received HU for at least 12 weeks, have been receiving a stable dose before screening, and still have symptoms related to PV will be enrolled.

Subjects will be randomized (1:1) to 1 of 2 treatment arms:

A: ruxolitinib and HU-placebo B: HU and ruxolitinib-placebo

Subjects randomized to either arm may be eligible to transition to open-label ruxolitinib after Week 16.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • Polycythemia Vera
  • PV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must currently be reporting symptoms while on a stable dose of HU monotherapy and be eligible to continue HU on study after randomization.
  • Before screening, the subject must have been receiving HU for at least 12 weeks AND be receiving a stable dose.
  • Subjects must meet baseline symptom criteria
  • Subjects should meet at least 1 of the following criteria:

    • No more than 2 phlebotomies within the 6 months before screening OR
    • No palpable splenomegaly.
  • Subjects must have a hematocrit that can be controlled within 35% to 48% (inclusive) before randomization.

Exclusion criteria

Exclusion Criteria:

  • Subjects with inadequate liver or renal function at screening.
  • Subjects with infection that requires therapy
  • Subjects with known active hepatitis A, B, or C at screening or with known positivity.
  • Subjects with an active over the previous 2 years
  • Subjects with clinically significant cardiac disease (Class III or IV).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    ruxolitinib and hydroxyurea (HU)-placebo

    Drug: Ruxolitinib · Drug: HU-placebo

  • Active comparator
    HU and ruxolitinib-placebo

    Drug: Hydroxyurea (HU) · Drug: Ruxolitinib-placebo

Interventions

  • Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.

  • DrugHydroxyureaStudies of HydroxyureaHydroxyurea pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.

  • DrugHU-placebo

    All placebo will be self-administered, and dosing will be the same as with the blinded dose. When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.

  • DrugRuxolitinib-placebo

    All placebo will be self-administered, and dosing will be the same as with the blinded dose. When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary

    Symptoms of polycythemia vera were assessed using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) electronic diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): tiredness, itching, muscle aches, night sweats, and sweats while awake. The total symptom score ranged from 0-50 and was calculated as the sum of the 5 symptom scores. A higher score indicates worse symptoms.

    Time frame: From Baseline to Week 16

Secondary outcomes

  1. Percentage of Subjects Achieving ≥ 50% Improvement From Baseline in the Individual Symptom Scores for TSS-C at Week 16

    The TSS-C cluster includes tiredness, itching, muscle aches, night sweats, and sweats while awake.

    Time frame: From Baseline to Week 16

  2. Proportion of Subjects Randomized to Ruxolitinib Who Achieved ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine and the Individual Symptom Scores at Week 16 That Were Maintained at Week 48

    Durable Response on TSS-C/individual symptoms defined as a ≥ 50% reduction in TSS-C/individual symptoms at Week 16 that were maintained at Week 48

    Time frame: Week 48

07

Results

Posted Apr 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinibHydroxyurea
Started5456
Completed4750
Not completed76
Withdrew: Adverse event41
Withdrew: Physician decision01
Withdrew: Subject decision32
Withdrew: Disease progression01
Withdrew: Reason for discontinuation not available01

Outcome measures

PrimaryPercentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary

Symptoms of polycythemia vera were assessed using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) electronic diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): tiredness, itching, muscle aches, night sweats, and sweats while awake. The total symptom score ranged from 0-50 and was calculated as the sum of the 5 symptom scores. A higher score indicates worse symptoms.

Time frame:
From Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary
Percentage of participantsRuxolitinibHydroxyurea
Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary43.429.6
Statistical analysis
  • Ruxolitinib vs Hydroxyurea · Chi-squared · p = 0.139 · Odds ratio (or): 1.82 · 95% CI 0.82 to 4.04
SecondaryPercentage of Subjects Achieving ≥ 50% Improvement From Baseline in the Individual Symptom Scores for TSS-C at Week 16

The TSS-C cluster includes tiredness, itching, muscle aches, night sweats, and sweats while awake.

Time frame:
From Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving ≥ 50% Improvement From Baseline in the Individual Symptom Scores for TSS-C at Week 16
Percentage of participantsRuxolitinibHydroxyurea
Tiredness (n= 50, 53)40.026.4
Itching (n= 48, 50)54.232.0
Muscle aches (n= 47, 49)38.330.6
Night sweats (n= 42, 48)47.641.7
Sweats while awake (n= 42, 46)54.834.8
SecondaryProportion of Subjects Randomized to Ruxolitinib Who Achieved ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine and the Individual Symptom Scores at Week 16 That Were Maintained at Week 48

Durable Response on TSS-C/individual symptoms defined as a ≥ 50% reduction in TSS-C/individual symptoms at Week 16 that were maintained at Week 48

Time frame:
Week 48
Reported as:
Number · percentage of participants
Proportion of Subjects Randomized to Ruxolitinib Who Achieved ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine and the Individual Symptom Scores at Week 16 That Were Maintained at Week 48
percentage of participantsRuxolitinib
TSS-C31.5 (19.5 to 45.6)
Tiredness24.1 (13.5 to 37.6)
Itching37.0 (24.3 to 51.3)
Muscle aches20.4 (10.6 to 33.5)
Night sweats29.6 (18.0 to 43.6)
Sweats while awake37.0 (24.3 to 51.3)

Adverse events

Collected over The duration of the study up to Week 16. This time frame defines the blinded, comparative phase of the study where the majority of patients remained on their original randomized assignment and exposure between ruxolitinib and hydroxyurea was similar.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib—5/54 (9.3%)50/54 (92.6%)
Hydroxyurea—4/56 (7.1%)45/56 (80.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventRuxolitinibHydroxyurea
Angina unstableCardiac disorders1/540/56
Arterial occlusive diseaseVascular disorders1/540/56
Cerebral ischemiaNervous system disorders1/540/56
Chest discomfortGeneral disorders1/540/56
Platelet count increasedInvestigations1/540/56
SpondylolisthesisMusculoskeletal and connective tissue disorders1/540/56
Deep vein thrombosisVascular disorders0/541/56
HematuriaRenal and urinary disorders0/541/56
Hemoglobin decreasedInvestigations0/541/56
HydronephrosisRenal and urinary disorders0/541/56
Most frequent other events
Showing 10 of 63
Most frequent other events
EventRuxolitinibHydroxyurea
FatigueGeneral disorders11/546/56
DiarrheaGastrointestinal disorders5/5411/56
HeadacheNervous system disorders9/543/56
AnemiaBlood and lymphatic system disorders8/545/56
DizzinessNervous system disorders7/545/56
ConstipationGastrointestinal disorders4/547/56
RashSkin and subcutaneous tissue disorders6/540/56
NauseaGastrointestinal disorders6/543/56
PruritusSkin and subcutaneous tissue disorders6/546/56
ThrombocytopeniaBlood and lymphatic system disorders2/545/56

Baseline characteristics

Age, Continuous
Age, Continuous(years)RuxolitinibHydroxyureaTotal
Mean63.1 ± 11.6864.2 ± 12.6863.7 ± 12.15
Sex: Female, Male
Sex: Female, Male(Participants)RuxolitinibHydroxyureaTotal
Female302252
Male243458
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RuxolitinibHydroxyureaTotal
White or Caucasian5356109
Asian101
08

Study locations

70 sites
  • Scottsdale, Arizona, United States
  • Fayetteville, Arkansas, United States
  • Burbank, California, United States
  • Glendale, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Stamford, Connecticut, United States
  • Washington, D.C., District of Columbia, United States
  • Boynton Beach, Florida, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Niles, Illinois, United States
  • Springfield, Illinois, United States
  • Ames, Iowa, United States
  • Westwood, Kansas, United States
  • Alexandria, Louisiana, United States
  • Baltimore, Maryland, United States
  • Southfield, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Columbia, Missouri, United States
  • Saint Louis, Missouri, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • East Orange, New Jersey, United States
  • Morristown, New Jersey, United States
  • Somerville, New Jersey, United States
  • Albany, New York, United States
  • Armonk, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Canton, Ohio, United States
  • Bethlehem, Pennsylvania USA, United States
  • Charleston, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Amarillo, Texas, United States
  • Bedford, Texas, United States
  • Dallas, Texas, United States
  • Garland, Texas, United States
  • Houston, Texas, United States
  • Longview, Texas, United States
  • Midland, Texas, United States
  • San Antonio, Texas, United States
  • Temple, Texas, United States
  • Tyler, Texas, United States
  • Salt Lake City, Utah, United States
  • Alexandria, Virginia, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Antwerpen, Belgium
  • Brugge, Belgium
  • Aachen, Germany
  • Berlin, Germany
  • Freiburg, Germany
  • Hamburg, Germany
  • Stuttgart, Germany
  • Ulm, Germany
  • Galway, Ireland
  • Firenze, Italy
  • Reggio Calabria, Italy
  • Varese, Italy
  • Barcelona, Spain
  • Pamplona, Spain
  • Salamanca, Spain
  • Boston, United Kingdom
  • Leicester, United Kingdom
  • Nottingham, United Kingdom
  • West Bromwich, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Mar 2014 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 1 month after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2012
First posted
Jul 3, 2012
Start
Jun 2012
Primary completionActual
Mar 2014
CompletionActual
May 2016
Results delay requested
Apr 3, 2014
Results first posted
Apr 7, 2015
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01632904
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 3, 2012
Start date
Jun 2012
Primary completion
Mar 2014
Completion
May 2016
Results posted
Apr 7, 2015
Last update
Nov 14, 2017

Study contacts

Mark Jones, M.D.
study director · Incyte Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion